Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 111

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 111
---
 independent registered public accounting FOR #P9# #P9# #P9# firm for our fiscal year ending December 31, 2025. 3. To approve, on an advisory basis, the compensation paid to our named executive officers. FOR #P10# #P10# #P10# 4. To approve an amendment to the Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan to FOR #P11# #P11# #P11# increase the number of common shares available thereunder by 19,500,000. Note: By signing this Proxy Card, you acknowledge that if other matters are properly brought before the meeting or any adjournment or postponement thereof, the Named Proxies are authorized to vote on those matters as the Named Proxies, or either of them, deem advisable, in their discretion. Check here if you would like to attend the meeting in person. Authorized Signatures - Must be completed for your instructions to be executed. Please sign exactly as your name(s) appears on your account. If held in joint tenancy, all persons should sign. Trustees, administrators, etc., should include title and authority. Corporations should provide full name of corporation and title of authorized officer signing this Proxy Card. Signature (and Title if applicable) Signature (if held jointly)